Status:
RECRUITING
Current Status of BTKi Treatment for CLL/SLL in China
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
CLL/SLL
Eligibility:
All Genders
18-80 years
Brief Summary
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- Patients with a confirmed diagnosis of CLL/SLL;
- Received BTK inhibitor treatment between February 2023 and February 2024.
Exclusion
- Patients with other types of lymphoma;
- Cases deemed unsuitable for inclusion in this study by the investigators.
Key Trial Info
Start Date :
July 13 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 12 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06508684
Start Date
July 13 2024
End Date
July 12 2025
Last Update
July 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China, 210029